Abstract
Background: The Long QT Syndrome (LQTS) is a genetic channelopathy with life‐threatening implications. The LQT3 form of this disease is caused by mutations of the SCN5A sodium‐channel gene. A specific mutation, SCN5A:ΔKPQ, is associated with repetitive reopenings of the sodium channel and prolonged inward current. This dominant inward current is manifest on the electrocardiogram as QT prolongation. Flecainide is a potent blocker of the open sodium channel.
Methods and Results: The effect of flecainide on the duration of the QT‐interval and the T‐wave morphology was systematically evaluated in five male patients age 2–64 years having the SCN5A:ΔKPQ mutation. After baseline electrocardiograms were obtained, low‐dose oral flecainide was administered for 48 hours. Serial electrocardiograms and blood flecainide levels were obtained during flecainide therapy. The QTc interval decreased on average by 104 ms, from a baseline value of 565 ± 60 ms to 461 ± 23 ms (P < 0.04) at a mean flecainide level of 0.28 ± 0.08 mg/L, with shortening of the QTonset interval (P < 0.003) and normalization of T‐wave morphology. The effects of flecainide were compared with oral mexiletine in two patients, with flecainide showing greater QTc shortening and more complete normalization of repolarization. No adverse side effects or proarrhythmia were observed with flecainide in this study.
Conclusion: Low‐dose, oral flecainide consistently shortened the QTc interval and normalized the repolarization T‐wave pattern in five LQT3 patients with SCN5A:ΔKPQ mutation. This preliminary study indicates that low‐dose flecainide is a promising therapeutic agent for LQTS patients with the SCN5A:ΔKPQ sodium channel mutation. A.N.E. 2001;6(2):153–158
Keywords: long QT syndrome, ion channels, antiarrhythmia agents, genetics
REFERENCES
- 1. Moss AJ, Schwartz PJ, Crampton RS, et al. The long QT syndrome: Prospective longitudinal study of 328 families. Circulation 1991;84:1136–1144. [DOI] [PubMed] [Google Scholar]
- 2. Keating M, Atkinson D, Dunn C, et al. Linkage of a cardiac arrhythmia, the long QT syndrome, and the Harvey ras‐1 gene. Science 1991;252:704–706. [DOI] [PubMed] [Google Scholar]
- 3. Curran ME, Splawski I, Timothy KW, et al. A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell 1995;80:795–803. [DOI] [PubMed] [Google Scholar]
- 4. Wang Q, Curran ME, Splawski I, et al. Positional cloning of a novel potassium channel gene: KVLQT1 mutations cause cardiac arrhythmias. Nat Genet 1996;12:17–23. [DOI] [PubMed] [Google Scholar]
- 5. Wang Q, Shen J, Splawski I., et al. SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome. Cell 1995;80:805–811. [DOI] [PubMed] [Google Scholar]
- 6. Splawski I, Tristani‐Firouzi M, Lehmann MH, et al. Mutations in the hminK gene cause long QT syndrome and suppress IKs function. Nat Genet 1997;17:338–340. [DOI] [PubMed] [Google Scholar]
- 7. Abbott GW, Sesti F, Splawski I, et al. MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia. Cell 1999;97:175–187. [DOI] [PubMed] [Google Scholar]
- 8. Dumaine R, Wang Q, Keating MT, et al. Multiple mechanisms of Na+ channel‐linked long‐QT syndrome. Circ Res 1996;78:916–924. [DOI] [PubMed] [Google Scholar]
- 9. Yamagishi H, Furutani M, Kamisago M, et al. A de novo missense mutation (R1623Q) of the SCN5A gene in a Japanese girl with sporadic long QT syndrome. Mutations in brief no. 140 Online. Hum Mutat 1998;11:481. [DOI] [PubMed] [Google Scholar]
- 10. Wei J, Wang DW, Alings M, et al. Congenital long‐QT syndrome caused by a novel mutation in a conserved acidic domain of the cardiac Na+ channel. Circulation 1999;99:3165–3171. [DOI] [PubMed] [Google Scholar]
- 11. Bennett PB, Yazawa K, Makita N, et al. Molecular media nism for an inherited cardiac arrhythmia. Nature 1995;376: 683–685. [DOI] [PubMed] [Google Scholar]
- 12. Moss AJ, Zareba W, Benhorin J, et al. Electrocardiographic T‐wave patterns in genetically distinct forms of the hereditary long‐QT syndrome. Circulation 1995;92:2929–2934. [DOI] [PubMed] [Google Scholar]
- 13. Schwartz PJ, Priori SG, Locati EH, et al. Long QT syndrome patients with mutations of the SCN5A and HERG genes have differential responses to Na+ channel blockade and to increases in heart rate: Implications for gene‐specific therapy. Circulation 1995;92:3381–3386. [DOI] [PubMed] [Google Scholar]
- 14. Rosero SZ, Zareba W, Robinson JL, et al. Gene‐specific therapy for long QT syndrome: QT shortening with lidocaine and tocainide in patients with mutation of the sodium channel gene. Ann Noninvas Electrocardiol 1997;3:274–278. [Google Scholar]
- 15. Benhorin J, Taub R, Goldmit M, et al. Effects of flecainide in patients with a new SCN5A mutation: Mutation‐specific therapy for long QT syndrome Circulation 2000;(in press). [DOI] [PubMed] [Google Scholar]
- 16. An RH, Wang XL, Kerem B, et al. Novel LQT‐3 mutation affects Na+ channel activity through interactions between alpha‐ and betal‐subunits. Circ Res 1998;83:141–146. [DOI] [PubMed] [Google Scholar]
- 17. Nagatomo T, January CT, Makielski JC. Preferential block of late sodium current in the LQT3 & Delta;KPQ Mutant by the class Ic antiarrhythmic flecainide. Molecular Pharm 2000;(in press). [PubMed] [Google Scholar]
- 18. Roden DM, Woosley R. Flecainide. N Engl J Med 1986;315: 36–41. [DOI] [PubMed] [Google Scholar]
- 19. Echt DS, Liebson PR, Mitchell LB, et al., and The CAST Investigators. Mortality and morbidity in patients randomized to receive encainide, flecainide, or placebo in the Cardiac Arrhythmia Suppression Trial. N Engi J Med 1991;324:781–788. [DOI] [PubMed] [Google Scholar]
- 20. Chen Q, Kirsch GE, Zhang D, et al. Genetic basis and molecular mechanism for idiopathic ventricular fibrillation. Nature 1998;392:293–296. [DOI] [PubMed] [Google Scholar]
- 21. Alshinawi CR, Veldkamp MW, Van Den Berg MP, et al. A single sodium channel mutation causing both long QT‐ and Brugada syndrome. Circulation 1999;100:1–494. [DOI] [PubMed] [Google Scholar]